| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In a concentration-dependent manner, SIAIS178 (1-100 nM) dramatically decreased BCR-ABL protein levels throughout a 16-hour period. The phosphorylation of BCR-ABL and its substrate STAT5 is strongly inhibited by SIAIS178 [1]. It has been observed that SIAIS178 (1, 10, 100, and 1000 nM) significantly inhibits the proliferation of BCR-ABL-driven CML cell lines. When used against BCR-ABL driven cell lines, SIAIS178 maintains its efficacy and selectivity [1].
|
|---|---|
| ln Vivo |
SIAIS178 (ip; 5, 15 and 45 mg/kg; 12 days) attenuates tumor development in a dose-dependent manner as demonstrated by serial volume assessments [1]. SIAIS178 (intravenous or intraperitoneal injection; 2 mg/kg; 24 hours) exhibits a T1/2 of 3.82 hours and 12.35 hours, with a Cmax of 1165.2 nM and 30 nM for intravenous and intraperitoneal administration, respectively [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: K562 Cell Tested Concentrations: 1, 3, 10, 30, 100 nM Incubation Duration: 16 hrs (hours) Experimental Results: Dramatically diminished BCR-ABL protein levels in a concentration-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Female Wistar rat [1]
Doses: 2 mg/kg (pharmacokinetic/PK/PK analysis) Route of Administration: intravenous (iv) (iv)injection or intraperitoneal (ip) injection; 24-hour Experimental Results: T1/2 of intravenous (iv) (iv)injection and intraperitoneal (ip) injection are respectively 3.82 and 12.35 hrs (hrs (hours)), Cmax were 1165.2 nM and 30 nM respectively. |
| References |
| Molecular Formula |
C50H62CLN11O6S2
|
|---|---|
| Molecular Weight |
1012.68038702011
|
| Exact Mass |
1011.401
|
| CAS # |
2376047-73-1
|
| PubChem CID |
139474625
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.5
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
70
|
| Complexity |
1750
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
ClC1=CC=CC(C)=C1NC(C1=CN=C(NC2=CC(=NC(C)=N2)N2CCN(C(CCCCCCC(N[C@H](C(N3C[C@@H](C[C@H]3C(NCC3C=CC(C4=C(C)N=CS4)=CC=3)=O)O)=O)C(C)(C)C)=O)=O)CC2)S1)=O
|
| InChi Key |
YGQREOJIRFCRKQ-ZIBKGDFVSA-N
|
| InChi Code |
InChI=1S/C50H62ClN11O6S2/c1-30-12-11-13-36(51)43(30)59-47(67)38-27-53-49(70-38)57-39-25-40(56-32(3)55-39)60-20-22-61(23-21-60)42(65)15-10-8-7-9-14-41(64)58-45(50(4,5)6)48(68)62-28-35(63)24-37(62)46(66)52-26-33-16-18-34(19-17-33)44-31(2)54-29-69-44/h11-13,16-19,25,27,29,35,37,45,63H,7-10,14-15,20-24,26,28H2,1-6H3,(H,52,66)(H,58,64)(H,59,67)(H,53,55,56,57)/t35-,37+,45-/m1/s1
|
| Chemical Name |
N-(2-chloro-6-methylphenyl)-2-[[6-[4-[8-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-8-oxooctanoyl]piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
|
| Synonyms |
SIAIS178 SIAIS-178
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~300 mg/mL (~296.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (7.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9875 mL | 4.9374 mL | 9.8748 mL | |
| 5 mM | 0.1975 mL | 0.9875 mL | 1.9750 mL | |
| 10 mM | 0.0987 mL | 0.4937 mL | 0.9875 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
